Trial Profile

Phase II Single Arm Study With CABozantinib in Non-Small Cell Lung Cancer Patients With MET Deregulation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms CABinMET

Most Recent Events

10 Sep 2019 According to trial design presented at the 20th World Conference on Lung Cancer, six of planned 25 patients have been enrolled.
10 Sep 2019 Trial design presented at the 20th World Conference on Lung Cancer.
15 Apr 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com